{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:35:51Z","timestamp":1768908951122,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":1036,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1111\/ajt.15560","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T10:23:33Z","timestamp":1565346213000},"page":"172-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation"],"prefix":"10.1016","volume":"20","author":[{"given":"Flavio","family":"Vincenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Klintmalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ram Peddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Blahunka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Conkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Holman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1111\/ajt.15560_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2004-04-1596","article-title":"The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation","volume":"105","author":"Riley","year":"2005","journal-title":"Blood."},{"issue":"1","key":"10.1111\/ajt.15560_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev."},{"issue":"3","key":"10.1111\/ajt.15560_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15560_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15560_bib5","unstructured":"FDA. Belatacept prescribing information. https:\/\/packageinserts.bms.com\/pi\/pi_nulojix.pdf. Accessed December 2018."},{"issue":"S1","key":"10.1111\/ajt.15560_bib6","first-page":"191","article-title":"Preliminary results of the use of humanized anti-CD54 in human renal allotransplantation","volume":"1","author":"Kirk","year":"2001","journal-title":"Am J Transplant."},{"issue":"5","key":"10.1111\/ajt.15560_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","article-title":"The role of CD40 and CD154\/CD40L in dendritic cells","volume":"21","author":"Ma","year":"2009","journal-title":"Semin Immunol."},{"issue":"11","key":"10.1111\/ajt.15560_bib8","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.4049\/jimmunol.171.11.5707","article-title":"CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses","volume":"171","author":"Lee","year":"2003","journal-title":"J Immunol."},{"key":"10.1111\/ajt.15560_bib9","first-page":"852571","article-title":"The activation of macrophage and upregulation of CD40 costimulatory molecule in lipopolysaccharide-induced acute lung injury","volume":"2008","author":"Dong","year":"2008","journal-title":"J Biomed Biotechnol."},{"issue":"2","key":"10.1111\/ajt.15560_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/kel229","article-title":"Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis","volume":"46","author":"Daoussis","year":"2007","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"10.1111\/ajt.15560_bib11","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/ajt.12678","article-title":"Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects","volume":"14","author":"Okimura","year":"2014","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15560_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism","volume":"8","author":"Andr\u00e9","year":"2002","journal-title":"Nat Med."},{"issue":"5","key":"10.1111\/ajt.15560_bib13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.TP.0000054835.58014.C2","article-title":"Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates","volume":"75","author":"Haanstra","year":"2003","journal-title":"Transplantation."},{"issue":"7","key":"10.1111\/ajt.15560_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00007890-200210150-00006","article-title":"Anti-CD40 therapy extends renal allograft survival in rhesus macaques","volume":"74","author":"Pearson","year":"2002","journal-title":"Transplantation."},{"issue":"4","key":"10.1111\/ajt.15560_bib15","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/ajt.12082","article-title":"A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects","volume":"13","author":"Goldwater","year":"2013","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.15560_bib16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.15560_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/imt.15.1","article-title":"Novel insights into anti-CD40\/CD154 immunotherapy in transplant tolerance","volume":"7","author":"Pinelli","year":"2015","journal-title":"Immunotherapy."},{"issue":"S2","key":"10.1111\/ajt.15560_bib18","first-page":"438","article-title":"A novel full human anti-CD40 monoclonal antibody, ASKP1240, mono- and comibnation-therapy in prolongation of renal allograft survival in Cynomolgus monkeys","volume":"11","author":"Song","year":"2011","journal-title":"Am J Transplant."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15560","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15560","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522100523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522100523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:25:54Z","timestamp":1761629154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522100523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1600613522100523"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15560","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}